Dr. Pan Zheng cofounded OncoImmune and served as Chief Medical Officer (CMO) until its acquisition by Merck. Dr. Zheng led OncoImmune’s clinical development, including the first-in-human trials in healthy volunteers and patients with cancer, as well as the successful completion of a phase 2 and phase 3 clinical trial establishing the safety and therapeutic efficacy of OncoImmune’s flagship products.

Prior to serving as OncoC4’s CMO, Dr. Zheng was on faculty in multiple academic institutions, including Ohio State University, the Children’s National Medical Center, and the Institute of Human Virology at the University of Maryland School of Medicine. He was trained in anatomic and clinical pathology and is a board-certified physician with the American Board of Pathology.